Celldex 制药

最新新闻

• 评级变动
  Guggenheim Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $100
  \u5e02\u573a\u8d44\u8baf · 2026/7/20
• Morgan Stanley Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $57
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $40 to $70
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 评级变动
  Analysts Are Bullish on These Healthcare Stocks: Celldex (CLDX), Belite Bio, Inc. ADR (BLTE)
  TipRanks · 2026/7/22
• 评级变动
  LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $56
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• 评级变动
  Cantor Fitzgerald Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $67
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  Wolfe Research Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $44
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION), Celldex (CLDX) and Jazz Pharmaceuticals (JAZZ)
  TipRanks · 2026/6/18
• 评级变动
  Wells Fargo Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $72
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $64
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $50 to $100
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $67
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $42 to $56
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  Wells Fargo Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $54
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64
  \u5e02\u573a\u8d44\u8baf · 2026/10/3
• 评级变动
  H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  Morgan Stanley Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $50
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $42 to $100
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $50 to $88
  \u5e02\u573a\u8d44\u8baf · 2026/9/24

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。